VIDEO: Genomic test results vary in Black women with breast cancer
Click Here to Manage Email Alerts
In this video, Holly Pederson, MD, assistant professor of medicine in the Cleveland Clinic Lerner College of Medicine of Case Western University, spoke with Healio about a study comparing results from two genomic risk of recurrence assays among Black women with breast cancer.
The results were presented at ASCO 2021.
In the retrospective analysis, researchers compared the concordance of a 70-gene signature — MammaPrint —and a 21-gene assay — Oncotype DX — among African American women with breast cancer included in two prospective observational registry trials.
Researchers found that the overall discordance between the two genomic assays among Black women included in the study was 51%.
“There may be a miscalibration in the Oncotype DX intermediate range test, such that Black women tested intermediate with Oncotype and may have tested high with MammaPrint, meaning that they may have benefitted with chemotherapy,” Pederson said. “More studies need to be done to look into this in more detail.”
Collapse
Read more about
Click Here to Manage Email Alerts